Pulmatrix Operating Income from 2010 to 2026
| PULM Stock | USD 2.49 0.08 3.11% |
Operating Income | First Reported 2012-06-30 | Previous Quarter -1.5 M | Current Value -866 K | Quarterly Volatility 2.4 M |
Check Pulmatrix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmatrix's main balance sheet or income statement drivers, such as Interest Expense of 197.6 K, Other Operating Expenses of 19 M or Research Development of 11.1 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.13 or PTB Ratio of 3.11. Pulmatrix financial statements analysis is a perfect complement when working with Pulmatrix Valuation or Volatility modules.
Pulmatrix | Operating Income | Build AI portfolio with Pulmatrix Stock |
Evaluating Pulmatrix's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Pulmatrix's fundamental strength.
Latest Pulmatrix's Operating Income Growth Pattern
Below is the plot of the Operating Income of Pulmatrix over the last few years. Operating Income is the amount of profit realized from Pulmatrix operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Pulmatrix is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Pulmatrix's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmatrix's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Pulmatrix Operating Income Regression Statistics
| Arithmetic Mean | (12,391,220) | |
| Coefficient Of Variation | (67.37) | |
| Mean Deviation | 7,188,970 | |
| Median | (9,862,000) | |
| Standard Deviation | 8,348,080 | |
| Sample Variance | 69.7T | |
| Range | 24.8M | |
| R-Value | (0.37) | |
| Mean Square Error | 63.9T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (619,008) | |
| Total Sum of Squares | 1115T |
Pulmatrix Operating Income History
Other Fundumenentals of Pulmatrix
Pulmatrix Operating Income component correlations
Click cells to compare fundamentals
About Pulmatrix Financial Statements
Pulmatrix investors utilize fundamental indicators, such as Operating Income, to predict how Pulmatrix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -8.8 M | -9.2 M | |
| Non Operating Income Net Other | -8.5 M | -8.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Pulmatrix Correlation against competitors. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.69) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.